title: cAMP enhances estrogen-related receptor alpha (ERRalpha) transcriptional activity at the SP-A promoter by increasing its interaction with protein kinase A and steroid receptor coactivator 2 (SRC-2).
abstract: Estrogen-related receptor (ERRalpha) plays a critical role in basal and cAMP-induced expression of the human surfactant protein-A (SP-A) gene in lung type II cells through direct binding to an ERR response element (ERRE, 5'-TGACCTTA-3') within its 5'-flanking region. Furthermore, protein kinase A (PKA) up-regulates ERRalpha activation of the hSP-A promoter. In the present study, using cultured human fetal lung type II cells, we observed that cAMP enhanced ERRalpha phosphorylation and nuclear expression levels. cAMP/PKA stimulation of ERRalpha activation of the SP-A promoter was blocked by the PKA inhibitor, H89, whereas the MAPK P38 inhibitor, SB203580, and the MAPK kinase inhibitor, PD98059, had negligible to modest effects. This suggests that cAMP acts selectively through PKA to increase ERRalpha transcriptional activity. Of several coactivators tested, steroid receptor coactivator 2 (SRC-2) had the most pronounced effect to increase ERRalpha transcriptional activity at the SP-A promoter; this was enhanced by cotransfection with PKA catalytic subunit (PKAcat). Interestingly, SRC-2, ERRalpha, and PKAcat in type II cell nuclear extracts interacted at the ERRE; this was enhanced by cAMP and inhibited by H89. cAMP increased in vivo binding of PKAcat and SRC-2 to the ERRE genomic region in lung type II cells. In mutagenesis studies, three serines (S87, S114, and S277) were found to be critical for PKA and SRC-2 induction of ERRalpha transcriptional activity. Collectively, these findings indicate that cAMP/PKA signaling enhances ERRalpha phosphorylation and nuclear localization, recruitment to the SP-A promoter, and interaction with PKAcat and SRC-2, resulting in the up-regulation of SP-A gene transcription.
authors.affiliation: Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, 75390-9038, USA.
authors.forename: Dongyuan
authors.initials: D
authors.lastname: Liu
authors.forename: Houda
authors.initials: H
authors.lastname: Benlhabib
authors.forename: Carole R
authors.initials: CR
authors.lastname: Mendelson
mesh_terms: D000818:Animals; D002467:Cell Nucleus / Q000187:drug effects / Q000378:metabolism; D000242:Cyclic AMP / Q000494:pharmacology*; D017868:Cyclic AMP-Dependent Protein Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004789:Enzyme Activation / Q000187:drug effects; D005333:Fetus / Q000166:cytology; D015894:Genome, Human / Q000235:genetics; D006801:Humans; D007546:Isoquinolines / Q000494:pharmacology; D008168:Lung / Q000166:cytology; D051379:Mice; D051958:Nuclear Receptor Coactivator 2 / Q000378:metabolism*; D010766:Phosphorylation / Q000187:drug effects; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011485:Protein Binding / Q000187:drug effects; D021381:Protein Transport / Q000187:drug effects; D037662:Pulmonary Surfactant-Associated Protein A / Q000235:genetics* / Q000378:metabolism; D011960:Receptors, Estrogen / Q000235:genetics* / Q000378:metabolism; D020218:Response Elements / Q000235:genetics; D012694:Serine / Q000378:metabolism; D013449:Sulfonamides / Q000494:pharmacology; D013912:Threonine / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*; D000097983:ERRalpha Estrogen-Related Receptor
chemical_list: D000242:Cyclic AMP; D017868:Cyclic AMP-Dependent Protein Kinases; D007546:Isoquinolines; D051958:Nuclear Receptor Coactivator 2; D037662:Pulmonary Surfactant-Associated Protein A; D011960:Receptors, Estrogen; D012694:Serine; D013449:Sulfonamides; D013912:Threonine; D000097983:ERRalpha Estrogen-Related Receptor; C063509:N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide